Current Report Pursuant to

Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) April 30, 2012




(Exact Name of Registrant as Specified in its Charter)




(State or Other Jurisdiction of Incorporation)


0-18281   04-2902449
(Commission File Number)   (I.R.S. Employer Identification No.)


35 Crosby Drive, Bedford, MA   01730
(Address of Principal Executive Offices)   (Zip Code)


(781) 999-7300

(Registrant’s Telephone Number, Including Area Code)



(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 7.01 Regulation FD Disclosure.


On April 30, 2012, Hologic, Inc., a Delaware corporation (“Hologic”), issued a joint press release with Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”), announcing that Hologic, Gold Acquisition Corp., a newly-formed Delaware corporation wholly-owned by Hologic (“Merger Sub”), and Gen-Probe had entered into an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Merger Sub will merge with and into Gen-Probe (the “Merger”) with Gen-Probe surviving the Merger as a wholly-owned direct subsidiary of Hologic. The transaction has been unanimously approved by the boards of directors of both Hologic and Gen-Probe. A copy of the joint press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.


Limitation on Incorporation by Reference. The information furnished in this Item 7.01, including the joint press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the joint press release attached as an exhibit hereto, the joint press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary notes in the joint press release regarding these forward-looking statements.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


99.1   Joint press release dated April 30, 2012 of Hologic, Inc. and Gen-Probe Incorporated.



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 30, 2012   HOLOGIC, INC.


        Glenn P. Muir
        Executive Vice President, Finance and Administration, and Chief Financial Officer